About Careers Internship MedBlog Contact us

BSI and Biogen Agrees to Develop New Therapies For Brain Disorders

by Medindia Content Team on September 26, 2007 at 5:55 PM
BSI and Biogen Agrees to Develop New Therapies For Brain Disorders

Johns Hopkins University's newly formed Brain Science Institute (BSI) and pharmaceutical development company Biogen Idec have agreed to collaborate on the development of new therapies for such neurodegenerative diseases as multiple sclerosis, Alzheimer's disease and Parkinson's disease.

The collaboration, which will run indefinitely, will be guided by a joint committee of representatives from Johns Hopkins and Biogen Idec. John Griffin, M.D., director of the BSI, will serve as the academic lead of the collaboration. He is a professor of neurology, neuroscience and pathology at Johns Hopkins and is the former director of the Johns Hopkins School of Medicine Department of Neurology. Griffin also is a longstanding participant in Biogen Idec's neurology scientific advisory board. The BSI is codirected by Rick Huganir, Ph.D., director of the Solomon Snyder Department of Neuroscience at Johns Hopkins.


The BSI was launched in March to speed the application of new discoveries to neurological diseases that currently have limited treatment options. Supported with a gift from an anonymous donor family, it brings together brain scientists from across the Hopkins schools and campuses to solve fundamental questions about brain development and function and to use these insights to understand the mechanisms of brain diseases, to develop effective treatments, and to take these therapies to patients.

"An important component of its mission is to foster translation of basic discovery into treatment," says Griffin, who is among the many Hopkins neuroscientists who collectively have more than 300 therapeutic and related patent applications. These inventions include candidate drugs for Alzheimer's disease and multiple sclerosis, novel cancer biomarkers, and a medical device for improved intracranial delivery of drugs.

The collaboration with the BSI would give Biogen Idec access to intellectual property to develop new neurological pharmaceuticals in exchange for research funding. Boards from both companies are expected to meet soon to select BSI projects to fund.

Source: John Hopkins
Font : A-A+



Recommended Readings

Latest Mental Health News

Predicting PTSD Resilience Through Post Traumatic Brain Activity
Studying brain circuits tied to PTSD's progression from acute to chronic states is vital for grasping its pathophysiology and crafting targeted treatments.
High Depression Rates Among Canadian COPD Patients During COVID-19
Older adults with COPD were roughly twice as likely to develop depression if they faced functional limitations.
Comparing Suicide Risk and Depression Screenings for Identifying Patient Risk
In most scenarios, depression screening tools demonstrated superior performance compared to suicide risk screenings.
Do People With Obsessive-Compulsive Disorder Experience More Intrusive Thoughts?
Experts suggest that identifying the distinctive traits specific to obsessive-compulsive disorder can aid individuals in comprehending the mental health disorder.
Brainwave Pattern In EEG Helps Track Depression in Healthy Individuals
Electroencephalogram (EEG), which tracks the electrical activity in the brain, can help in the early identification and prevention of depression.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

BSI and Biogen Agrees to Develop New Therapies For Brain Disorders Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests